title: Intrapulmonary production of RANTES during rejection and CMV pneumonitis after lung transplantation.
abstract: RANTES (regulated upon activation, normally T expressed and secreted) is a chemoattractant for macrophages, memory T lymphocytes, and eosinophils. We investigated whether intrapulmonary production of the chemokine RANTES contributes to the recruitment of immune cells during lung transplantation complications. RANTES concentration was measured in bronchoalveolar lavage (BAL) fluids using an ELISA assay. It was significantly higher during CMV pneumonitis (36.2 +/- l6 pg/ml, n=12, P=0.031) and allograft rejection (31.1 +/- 8.5 pg/ml, n=27, P=0.013) than in patients without complications (9.1 +/- 2.3 pg/ml, n=22). At least some of the RANTES was produced by lung macrophages: BAL macrophages cultured for 24 hr spontaneously released larger amount of RANTES during CMV pneumonitis (140 +/- 53 pg/ml, n=8, P=0.002) and allograft rejection (84 +/- 44 pg/ml, n=11, P=0.037) than in control patients (15.2 +/- 6.5 pg/ml, n=21). Moreover, macrophages in transbronchial biopsies were labeled by an anti-RANTES mAb. RANTES production by BAL macrophages was followed in 2 patients with CMV pneumonitis. It remained high as long as CMV-induced cytopathic effects or clinical symptoms were present, but it returned to baseline as the infection was controlled. These results suggest that the intrapulmonary production of the chemokine RANTES by activated macrophages contributes to the intrapulmonary accumulation of immune cells during complications of lung transplantation.
authors.affiliation: INSERM U131, Institute Paris Sud sur les Cytokines, France.
authors.forename: G
authors.initials: G
authors.lastname: Monti
authors.forename: A
authors.initials: A
authors.lastname: Magnan
authors.forename: M
authors.initials: M
authors.lastname: Fattal
authors.forename: B
authors.initials: B
authors.lastname: Rain
authors.forename: M
authors.initials: M
authors.lastname: Humbert
authors.forename: J L
authors.initials: JL
authors.lastname: Mege
authors.forename: M
authors.initials: M
authors.lastname: Noirclerc
authors.forename: P
authors.initials: P
authors.lastname: Dartevelle
authors.forename: J
authors.initials: J
authors.lastname: Cerrina
authors.forename: G
authors.initials: G
authors.lastname: Simonneau
authors.forename: P
authors.initials: P
authors.lastname: Galanaud
authors.forename: D
authors.initials: D
authors.lastname: Emilie
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D018893:Bronchoalveolar Lavage; D018946:Chemokine CCL5 / Q000096:biosynthesis* / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000378:metabolism*; D004804:Eosinophils / Q000166:cytology / Q000276:immunology; D015774:Ganciclovir / Q000627:therapeutic use; D006084:Graft Rejection / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D008168:Lung / Q000276:immunology / Q000378:metabolism*; D017563:Lung Diseases, Interstitial / Q000188:drug therapy / Q000378:metabolism*; D016040:Lung Transplantation / Q000009:adverse effects / Q000276:immunology*; D016676:Macrophages, Alveolar / Q000378:metabolism; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology
chemical_list: D000998:Antiviral Agents; D018946:Chemokine CCL5; D015774:Ganciclovir